Src inhibitors in lung cancer: current status and future directions.

Abstract

Src tyrosine kinases regulate multiple genetic and signaling pathways involved in the proliferation, survival, angiogenesis, invasion, and migration of various types of cancer cells They are frequently expressed and activated in many cancer types, including lung cancer. Several Src inhibitors, including dasatinib, saracatinib, bosutinib, and KX2-391, are… (More)
DOI: 10.3816/CLC.2010.n.030

Topics

Cite this paper

@article{Rothschild2010SrcII, title={Src inhibitors in lung cancer: current status and future directions.}, author={Sacha I. Rothschild and Oliver Gautschi and Eric B. Haura and Faye M. Johnson}, journal={Clinical lung cancer}, year={2010}, volume={11 4}, pages={238-42} }